Utrecht and Bergisch Gladbach, September 9, 2020

Miltenyi Biotec B.V. & Co. KG, a global provider of products and services for advancing biomedical research and cellular therapy, and MILabs B.V. announced today that Miltenyi has acquired a high-end MILabs VECTor OI/CT system. This hybrid Optical Imaging with in-line X-ray CT comes with a unique Duet Optical docking station so that both high-throughput 2D optical imaging as well as CT-guided 3D optical tomography of deep tissue can be performed. Moreover, the X-ray CT system enables diagnostic imaging including high-resolution soft-tissue visualization with contrast agents.

Stand alone optical and Optical/CT imaging system

“We are excited to add this advanced hybrid Optical/CT preclinical imaging system to our research platform” says Dr. Wa’el Al Rawashdeh, Ph.D, Group Leader Preclinical Studies, and Cell Tracking at Miltenyi Biotec. “By combining our expertise in cell analysis and innovative detection reagents and technologies we will be able to exploit MILabs’ VECTor OI/CT exclusive imaging capabilities to further develop pioneering tools and reagents for biomedical research, in particular cell and gene therapy, as well as preclinical and clinical cell-therapy tracking technologies”.

“Our mission has always been to develop and market new preclinical imaging technologies such as our hybrid 2D/3D Optical/CT system” explains Prof. Frederik Beekman, CEO/CSO of MILabs B.V. We are grateful that Miltenyi Biotec, which has extensive expertise in developing both optical and X-ray CT probes and contrast agents, has selected MILabs as its supplier for preclinical imaging products”.

About Miltenyi Biotec B.V. & Co. KG:

Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our technologies enable solutions for cellular research, cell therapy, cell manufacturing, and imaging. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Today, Miltenyi Biotec has more than 3,000 employees in 28 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health. www.miltenyibiotec.com

About MILabs B.V.:

This fast-growing Dutch company has a history of providing a continuum of innovations to expand the applications preclinical molecular imaging. With its latest adaptive platform, MILabs has succeeded at commercializing a scalable imaging platform, able to accommodate Optical and CT imaging as well as the nuclear PET and SPECT techniques. MILabs has built a strong brand based on its mission of “Making Molecular Imaging Clear”. With ultra-high-resolution and multiparametric imaging complemented by theranostic capabilities, it provides efficient translational systems for both diagnostic and therapy applications. For more information, visit:  www.milabs.com or contact MILabs at [email protected].

Share on social media

Spotlight on the Orthopedic Imaging at UMC Utrecht, the Netherlands – Prof. Harrie Weinans & Dr. Bart van der Wal

  – Spotlight on the Orthopedic Imaging at UMC Utrecht, the Netherlands –  – Prof. …

Read More →

Press Release: MILABS launches its 7th generation of preclinical imagers at the World Molecular Imaging Conference 2021

Under the new ownership of the Rigaku Group (Tokyo, Japan), MILabs is pushing the value …

Read More →

Press Release: RIGAKU Acquires Life Science Imaging Equipment Manufacturer MILabs

August 3, 2021 – Houten, the Netherlands Dear readers, We are very excited that MILabs …

Read More →

Press Release: Confocal PET Causes Spectral PET Breakthrough in Preclinical Imaging

Houten, the Netherlands – March 24, 2021 Using its unique Confocal PET technology, MILabs B.V …

Read More →

Spotlight on Akiva Mintz, MD, Ph.D. – Columbia University

Spotlight on Akiva Mintz, MD, Ph.D. – Columbia University – Bridging the “valley of death” …

Read More →

Spotlight on Bart Cornelissen, PhD – Department of Oncology, Oxford Institute for Radiation Oncology at University of Oxford

– Targeting Tumors from the inside –   Dr. Bart Cornelissen is Group Leader and …

Read More →

Spotlight on Prof. Twan Lammers – ExMI-RWTH Aachen

A Pioneering Mind in Nanomedicine and Theranostics Prof. Dr. Dr. Twan Lammers is Head of …

Read More →

Miltenyi Biotec strengthens its research capabilities for cell analysis and preclinical imaging by acquiring a MILabs’ premium Optical/CT imaging system

  Utrecht and Bergisch Gladbach, September 9, 2020 Miltenyi Biotec B.V. & Co. KG, a …

Read More →

MILabs announced the co-winners of the 2020 MILabs Image of the Year Award

September 4, 2020, Utrecht, The Netherlands Each year, at the occasion of the Annual Congress …

Read More →

Bayer AS installs top-of-the-line MILabs VECTor PET/SPECT/CT to advance its targeted alpha therapy programs

August 27, 2020, Oslo-Norway and Utrecht-The Netherlands Bayer AS has installed a state-of-the-art MILabs VECTor …

Read More →

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam On the frontline of fighting …

Read More →

The University of Southampton enters the field of Correlative In-Vivo Imaging by Acquiring MILabs 3D/4D Optical/CT

May 12, 2020, Southampton, UK – Utrecht, the Netherlands The Faculty of Medicine, University of …

Read More →
Scroll to Top